BERGEN, Norway, May 20, 2016 -- Further to the Marine Harvest share trading on the Oslo Stock Exchange excluding a dividend of NOK 1.70 per share, in the form of a repayment of paid-in capital, as from the 20th of May, the conversion price of the Company's EUR 375 million convertible bond (ISIN NO0010710395) has been adjusted.
The new conversion price is EUR 9.9226.
This information is subject of the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act
HUG#2014266
Contact:
Ivan Vindheim, CFO, Mobile: +47 958 71 310
Kim Galtung Døsvig, IR Officer & Head of Treasury, Mobile: +47 908 76 339


California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



